The fibrinolytic system in neoplasia

Seminars in Thrombosis and Hemostasis

Volumn 22, Issue 6, 1996, Pages 459-478

  Bell, William R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cancer prognosis; fibrinolysis; neoplasia; u PA; u PAR

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; UROKINASE RECEPTOR;

CANCER; FIBRINOLYSIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0030469517     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-999047     Document Type: Review

References (402)

1. Smith JA, WD Ross: Translation of Aristotle's De Partibus Animalium. Clarendon Press, Oxford, Book II, 1912, p 4.
2. Hunter J: Treatise on Blood, Inflammation, and Gunshot Wounds. G Nicoll, London, 1794, p 575.
3. Scherer J: Chemisch-physiologische Untersuchungen. Ann Chem Pharm 40:1-64, 1841.
4. MacFarlane RG, R Biggs: Fibrinolysis: Its mechanism and significance. Blood 3:1167-1187, 1948.
5. Green JR: Note on the action of sodium chloride in dissolving fibrin. J Physiol (London) 8:372-377, 1887.
6. Dastre A: Fibrinolyse dans le sang. Arch Physiol Norm Pathol 5:661-663, 1893.
7. Tillet WS, RL Garner: The fibrinolytic activity of hemolytic streptococci. J Exp Med 58:485-502, 1933.
8. Milstone H: A factor in normal human blood which participates in streptococcal fibrinolysis. J Immunol 42:109-116, 1941.
9. Kaplan MH: Nature and role of the lytic factor in hemolytic streptococcal fibrinolysis. Proc Soc Exp Biol Med 57:40-43, 1944.
10. Christensen LR, CM MacLeod: A proteolytic enzyme of serum: Characterization, activation and reaction with inhibitors. J Gen Physiol 28:559-583, 1945.
11. Sherry S: The fibrinolytic activity of streptokinase activated human plasmin. J Clin Invest 33:1054-1063, 1954.
12. Shulman S, N Alkjaersig, S Sherry: Physiochemical studies on human plasminogen (profibrinolysin) and plasmin (fibrinolysin). J Biol Chem 233:91-97, 1958.
13. Alkjaersig N, AP Fletcher, S Sherry: The activation of human plasminogen I. Spontaneous activation in glycerol. J Biol Chem 233:81-85, 1958.
14. Alkjaersig N, AP Fletcher, S Sherry: The activation of human plasminogen. II. A kinetic study of activation with trypsin. urokinase and streptokinase. J Biol Chem 233:86-90, 1958.
15. Fletcher AP, N Alkjaersig, S Sherry: The maintenance of a sustained thrombolytic state in man. I. Induction and effects. J Clin Invest 38:1096-1110, 1959.
16. Fletcher AP: The maintenance of a sustained thrombolytic state in man. H. Clinical observations on patients with myocardial infarction and other thromboembolic disorders. J Clin Invest 38: 1111-1119, 1959.
17. Johnson AJ, WR McCarty: The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase. J Clin Invest 38:1627-1643, 1959.
18. Sahli W: Über das Vorkommen von Pepsin and Trypsin in normalem menschlichen Harn. Pflügers Arch 36:209-228, 1885.
19. MacFarlane RG, J Pilling: Observations on fibrinolysis: Plasminogen, plasmin, and antiplasmin content of human blood. Lancet 2:562-565, 1946.
20. Williams JRB: The fibrinolytic activity in normal urine. Br J Exp Pathol 32:530-537, 1951.
21. Sobel GW: Urokinase: An activator of plasma profibrinolysis extracted from urine. Am J Physiol 171:768-769, 1952.
22. Astrup T, PM Permin: Fibrinolysis in the animal organism. Nature 159:681-682, 1947.
23. Astrup T, I Sterndorff: An activator of plasminogen in normal urine. Proc Soc Exp Biol Med 81:675-678, 1952.
24. Celender DR, MM Guest: The biochemistry and physiology of urokinase. Am J Cardiol 6:409-419, 1960.
25. Sawyer WD: Studies on the thrombolytic activity of human plasma. J Clin Invest 39:426-434, 1960.
26. Sherry S, N Alkjaersig: Studies on the activation of human plasminogen. J Clin Invest 35:735, 1956.
27. Sherry S, N Alkjaersig: Studies on the fibrinolytic enzyme of human plasma. Thromb Diath Haemorrh 1:264-288, 1957.
28. Sherry S, N Alkjaersig: Biochemical, experimental and clinical studies of proteolytic enzymes: With particular reference to the fibrinolytic enzyme of human plasma. Ann NY Acad Sci 68:52-66, 1957.
29. Sherry S, AP Fletcher, N Alkjaersig: Fibrinolysis and fibrinolytic activity in man. Physiol Rev 39:343-382, 1957.
30. Celender DR, RP Longlinais, MM Guest: The application of foam technique to the partial purification of a urine activator of plasma profibrinolysin. Arch Biochem Biophys 55:286-287, 1955.
31. Alkjaersig N, AP Fletcher, S Sherry: The mechanism of clot dissolution by plasmin. J Clin Invest 38:1086-1095, 1959.
32. Plough J, NO Kjeldgaard: Urokinase, an activator of plasminogen from human urine. Biochim Biophys Acta 24:278-289, 1957.
33. Squoris JT, JK Insman, KB McCall: The preparation of human urokinase. Am J Cardiol 6:406-408, 1960.
34. Lesuk A, L Terminiello, JH Traver: Crystalline human urokinase: Some properties. Science 147:880-882, 1965.
35. White WF, GH Barlow, MM Mozen: The isolation and characterization of plasminogen activators (urokinase from human urine). Biochemistry 5:2160-2169, 1966.
36. Sherry S, N Alkjaersig, AP Fletcher: Assays of urokinase preparations with the synthetic substrate acetyl-L-lysine methyl (ester). J Lab Clin Med 64:145-153, 1964.
37. Sherry S, AP Fletcher: Thrombolytic therapy. Am Heart J 61: 575-578, 1961.
38. Sherry S, AP Fletcher, N Alkjaersig: Developments in fibrinolytic therapy for thromboembolic disease. Ann Intern Med 50: 560-570, 1959.
39. Sherry S: Studies on enhanced fibrinolytic activity in man. J Clin Invest 38:810-822, 1959.
40. Lewis JH, JH Ferguson: Studies on a proteolytic enzyme system of the blood. II. Fibrinolysokinase activators for profibrinolysin. J Clin Invest 29:1059-1068, 1950.
41. Permin PM: Properties of the fibrinokinase-fibrinolysin system. Nature 60:571-578, 1947.
42. Tagnon HJ, GE Palade: Activation of proplasmin by a factor from mammalian tissue. J Clin Invest 29:317-324, 1950.
43. Castellino FJ: Biochemistry of human plasminogen. Semin Thromb Hemostas 10:18-23, 1984.
44. Swisshelm K: Localization of the plasminogen gene (PLG) to the distal portion of the long arm of chromosome 6 by in situ hybridization. Cytogenet Cell Genet 40:756, 1985.
45. Wiman B, P Wallén: On the primary structure of human plasminogen and plasmin. Purification and characterization of cyanogen-bromide fragments. Eur J Biochem 57:387-394, 1975.
46. Robbins KC: Further studies on the purification and characterization of human plasminogen and plasmin. J Biol Chem 240:541-550, 1965.
47. Collen D, M Verstraete: Molecular biology of human plasminogen. II. Metabolism in physiological and some pathological conditions in man. Thromb Diath Haemorrh 34:403-408, 1975.
48. Wiman B, P Wallén: The specific interaction between plasminogen and fibrin. A physiological role of the lysine binding site in plasminogen. Thromb Res 10:213-222, 1977.
49. Bick BL: The clinical significance of fibrinogen degradation products. Semin Thromb Hemostas 8:302-330, 1982.
50. Marsh N: Fibrinolysis. John Wiley & Sons, New York, 1981, pp 46-47.
51. Marder VJ, AZ Budzynski: The structure of fibrinogen degradation products. Prog Hemostas Thromb 2:141-174, 1974.
52. Niewiarowski S, AZ Budzynski, B Lipinski: Significance of the intact polypeptide chains of human fibrinogen in ADP-induced platelet aggregation. Blood 49:636-644, 1977.
53. Holt JC, M Mahmoud, PJ Gaffney: The ability of fibrinogen fragments to support ADP-induced platelet aggregation. Thromb Res 16:427-435, 1979.
54. Malofiejew M: The biological and pharmacological properties of some fibrinogen degradation products. Scand J Haematol 8:303-308, 1971.
55. LaDuca FM: Stimulation of fibrinogen synthesis in cultured rat hepatocytes by fibrinogen degradation product fragment D. Proc Natl Acad Sci USA 86:8788-8792, 1989.
56. Niewiarowski S, O Prou-Wartelle: Role du facteur contact (facteur Hageman) dans la fibrinolyse. Thromb Diath Haemorrh 3: 593-603, 1959.
57. Revak SD: Structural changes accompanying enzymatic activation of human Hageman factor. J Clin Invest 54:619-696, 1958.
58. Albrechtsen OK: The fibrinolytic agents in saline extracts of human tissues. Scand J Clin Lab Invest 10:91-96, 1958.
59. Wilson EL: Molecular species of plasminogen activators secreted by normal and neoplastic cells. Cancer Res 40:933-938, 1980.
60. Mullins DE, ST Rohrlich: The role of proteinases in cellular invasiveness. Biochim Biophys Acta 695:177-214, 1983.
61. Wallén P: Strucutral characterization of tissue plasminogen activator purified by immunosorbent chromatography. In: Davidson F, F Bachmann, CA Bouvier, EKO Kruithof (Eds): Progress in Fibrinolysis, vol 6. Churchill Livingstone, Edinburgh, 1983, pp 338-343.
62. Bachmann F, EKO Kruithof: Tissue plasminogen activator: Chemical and physiological aspects. Semin Thromb Hemostas 10:6-17, 1984.
63. Bachmann F: Fibrinolysis. In: Verstraete M, J Vermylen, HR Lijnen, J Arnout (Eds): Thrombosis and Haemostasis. Leuven University Press, Leuven, 1987, pp 233-235.
64. Rijken DC, M Hoylaerts, D Collen: Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. J Biol Chem 257:2920-2925, 1982.
65. Rijken DC: Measurement of human tissue-type plasminogen activator by two-site immunoradiometric assay. J Lab Clin Med 101:274-284, 1983.
66. Matsuo O: Turnover of tissue plasminogen activator in man. Thromb Haemostas 48:242, 1982.
67. Baughman RA: Pharmacokinetics of tissue plasminogen activator. In: Sobel BE, D Collen, EB Grossbard (Eds): Tissue Plasminogen Activator in Thrombolytic Therapy. Marcel Dekker, New York, 1987, pp 41-53.
68. Sprengers ED, C Kluft: Plasminogen activator inhibitors. Blood 69:381-387, 1987.
69. Darras V: Measurement of urokinase-type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies. Thromb Haemostas 56:411-414, 1986.
70. Ueno T, N Kobayashi, T Maekawa: Studies on metabolism of urokinase and mechanism of thrombolysis by urokinase. Thromb Haemostas 42:885-894, 1979.
71. Verstraete M: Biochemical and clinical aspects of thrombolysis. Semin Hematol 15:35-54, 1978.
72. Rajput B: Chromosomal locations of human tissue plasminogen activator and urokinase genes. Science 230:672-674, 1985.
73. Zamarron C: Biological and thrombolytic properties of proenzyme and active forms of human urokinase. I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology. Thromb Haemostas 52:19-23, 1985.
74. Lijnen HR, C Zamarron, M Blaber: Activation of plasminogen by prourokinase. I. Mechanism. J Biol Chem 261:1253-1258, 1986.
75. Larsson LI: Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse. J Cell Biol 98:894-903, 1984.
76. Dano K: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44:139-266, 1985.
77. Ohlsson M, XR Peng, YX Liu: Hormone regulation of tissue-type plasminogen activator gene expression and plasminogen activator mediated proteolysis. Semin Thromb Hemostas 17: 286-290, 1991.
78. Strickland S, WH Beers: Studies on the role of plasminogen activator in ovulation. J Biol Chem 18:5694-5702, 1976.
79. Galway B, M Oikawa, T Ny: Epidermal growth factor stimulates tissue plasminogen activator activity and messenger ribonucleic acid levels in cultured rat granulosa cells: Mediation by pathways independent of protein kinase A and C. Endocrinology 125:126-135, 1989.
80. Sappino AP, J Huarte, D Bellin: Plasminogen activators in tissue remodeling and invasion. J Cell Biol 109:2471-2479, 1989.
81. Feinberg RF, LC Kao, JE Haimowitz: Plasminogen activator inhibitor types 1 and 2 in human trophoblasts. Lab Invest 61:20-26, 1989.
82. Menoud PA, S Debrot, J Schowing: Mouse neural crest cells secrete both urokinase type and tissue type plasminogen activators in vitro. Development 106:685-690, 1989.
83. Erickson CA, RR Isseroff: Plasminogen activator activity is associated with neural crest cell motility in tissue culture. J Exp Zool 251:123-133, 1989.
84. Valinsky JE, E Reich, N LeDouarin: Plasminogen activator in the bursa of Fabricius: Correlations with morphogenetic remodeling and cell migrations. Cell 25:471-476, 1981.
85. Gudewicz PW, N Gilboa: Human urokinase-type plasminogen activator stimulates chemotaxis of human neutrophils. Biochem Biophys Res Commun 147:1176-1181, 1987.
86. Krawczyk WK: A pattern of epidermal cell migration during wound healing. J Cell Biol 49:247-263, 1971.
87. Astrup T: Blood coagulation and fibrinolysis in tissue culture and tissue repair. Biochem Pharmacol 17(Suppl):241-257, 1968.
88. Viziam CB, AG Matolsty, H Mescon: Epithelialization of small wounds. J Invest Dermatol 43:499-507, 1964.
89. Quax PHA, E Rrisal, N Pedersen: Cell surface plasminogen activation is required for differentiation of human adult myogenic cells in vitro. Thromb Hemostas (Abstr) 65:665, 1991.
90. Clowes AW, M Monika, YPT Clowes: Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 67:61-67, 1990.
91. Gross TJ, RH Simon, RG Sitrin: Expression of urokinase-type plasminogen activator by rat pulmonary alveolar epithelial cells. Am J Respir Cell Mol Biol 3:449-456, 1990.
92. Marshall BC, DS Sageser, NV Rao: Alveolar epithelial cell plasminogen activator. Characterization and regulation. J Biol Chem 265:8198-8204, 1990.
93. Moscatelli D, DB Rifkin: Membrane and matrix localization of proteinases: A common theme in tumor cell invasion and angiogenesis. Biochim Biophys Acta 948:67-85, 1988.
94. Ossowski L, D Biegel, E Reich: Mammary plasminogen activator: Correlation with involution, hormonal modulation and comparison between normal and neoplastic tissue. Cell 16:929-940, 1979.
95. Heimburger N, EP Paques, J Römisch: Coagulation and fibrinolysis in cancer. Behring Inst Mitt 91:169-182, 1992.
96. Pineo GF, E Regoeczi, MWC Hatton: The activation of coagulation by extract of mucus: A possible pathway of intravascular coagulation accompanying adenocarcinomas. J Lab Clin Med 82:225, 1973.
97. Goualt-Heilman M, E Chardon, C Sultan: The procoagulant factor of leukemia promyelocytes: Demonstration of immunologic cross-reactivity with human brain tissue factor. Br J Haematol 30:151, 1975.
98. Szezcpanski M, K Bardadin, J Zawadzki: Procoagulant activity of gastric, colorectal and renal cancer is factor VII dependent. J Cancer Res Clin Oncol 114:519, 1988.
99. Morgan D, RL Edward, FR Rickles: Monocyte procoagulant activity as a peripheral marker of clotting activation in cancer patients. Haemostasis 18:55, 1988.
100. Wilde JT, JM Davies: Haemostatic problems in acute leukemia. Blood Rev 4:245, 1990.
101. Larson RS, D Eilender, RA Waldmann: Evidence for 15; 17 translocation in every patient with acute promyelocytic leukemia. Am J Med 76:824, 1984.
102. Goldberg MA, D Ginsburg, RJ Mayer: Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia? Blood 69:187, 1987.
103. Hillestad LK: Acute promyelocytic leukemia. Acta Med Scand 159:189, 1957.
104. Bennett B, NA Booth, A Cruli: The bleeding disorder in acute promyelocytic leukemia: Fibrinolysis due to u-PA rather than defibrination. Br J Haematol 71:511-517, 1989.
105. Steerenberg L, HL Haak, EJP Brommer: Evidence of fibrinogen breakdown by leukocyte enzymes in a patient with acute promyelocytic leukemia. Haemostasis 15:126, 1985.
106. Schwartz BS, EC Williams, MG Conlan: Epsilon-aminocaproic acid in the treatment of patients with acute promyelocytic leukemia and acquired alpha-2 plasmin inhibitor deficiency. Ann Intern Med 105:873, 1986.
107. Bennett B, D Ogston: Fibrinolytic bleeding syndromes. In: Ratnoff OD, CD Forbes (Eds): Disorders of Hemostasis. Saunders, Philadelphia, 1991, p 327.
108. VanSlyck E, SBK Raman, N Janakiraman: Primary fibrinolysis in acute monocytic leukemia. Henry Ford Hosp Med J 37:33, 1989.
109. Gralnick HR, S Marchesi, H Giveller: Intravascular coagulation in acute leukemia: Clinical and subclinical abnormalities. Blood 40:709, 1972.
110. Sack GH, J Levin, WR Bell: Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: Clinical pathophysiologic and therapeutic features. Medicine 56:1-37, 1977.
111. Gasic GJ, TB Basic, N Galanti: Platelet tumor cell interaction in mice - the role of platelets in the spread of malignant disease. Int J Cancer 11:704-718, 1973.
112. Gastpar H: Platelet-cancer cell interaction in metastasis formation. A possible therapeutic approach to metastasis prophylaxis. J Med 8:102-114, 1977.
113. Gasic GJ, PAG Koch, B Hus: Thrombogenic activity of mouse and human tumors: Effects on platelets, coagulation and fibrinolysis and possible significance for metastasis. Kreb Klin Onkol 86:263-277, 1976.
114. Alkjaersig N: The antifibrinolytic activity of platelets. In: Johnson SA, RW Monto, JW Rebuck, RC Horn Jr (Eds): Blood Platelet. Little Brown, Boston, 1961, pp 329-336.
115. Kwaan HC, N Suwanwela: Inhibitors of fibrinolysis in platelets in polycythemia vera and thrombocytosis. Br J Haematol 21:313-322, 1971.
116. Erickson LA, MH Ginsberg, DJ Loskutoff: Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 74:1465-1472, 1984.
117. Gronke RS, DJ Knauer, S Veeraghavan: A form of protease nexin I is expressed on the platelet surface during the growth of a murine mammary adenocarcinoma. Int J Cancer 43:472-478, 1989.
118. Assoian RK, A Komoriya, CA Meyers: Transforming growth factor-β in human platelets. Identification of a major storage site, purification and characterization. J Biol Chem 258:7155-7160, 1983.
119. Keski-Oja J, AE Postlethwaite, HL Moses: Transforming growth factors in the regulation of malignant cell growth and invasion. Cancer Invest 6:705-724, 1988.
120. Busso N, D Belin, C Failly-Crepin: Plasminogen activators and their inhibitors in human mammary cell line (HBL-100): Modulation by glucocorticoids. J Biol Chem 261:9309-9315, 1986.
121. Gelehrter TD, R Sznycer-Laszuk, R Zeheb: Dexamethasone inhibition of tissue-type plasminogen activator (tPA) activity; paradoxical induction of both tPA antigen and plasminogen activator inhibitor. Mol Endocrinol 1:97-101, 1987.
122. Hovi T, O Saksela, A Vaheri: Increased secretion of plasminogen activator by human macrophages after exposure to leukocyte interferon. FEBS Lett 129:233-236, 1981.
123. Collart MA, D Belin, JD Vassalli: Gamma interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin-1 and urokinase genes which are controlled by short-lived repressors. J Exp Med 164:2113-2118, 1986.
124. Emeis JJ, T Kooistra: Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 163:1260-1266, 1966.
125. Schleef RR, MP Bevilacqua, M Sawdey: Cytokine activation of vascular endothelium: Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 263:5797-5803, 1988.
126. Lalho M, J Keski-Oja: Growth factors in the regulation of pericellular proteolysis: A review. Cancer Res 44:2535-2553, 1989.
127. Kessler TL, G Markus: Epidermal growth factor and 12-tetradecanoyl phorbol 13-acetate induction of urokinase in A431 cells. Semin Thromb Hemostas 17:217-224, 1991.
128. Keski-Oja J, K Koli, J Lohi: Growth factors in the regulation of plasminogen-plasmin system in tumor cells. Semin Thromb Hemostas 17:231-239, 1991.
129. Van Hinsberg VWM, EA van den Berg, W Fiers: Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells. Blood 75:1991-1998, 1990.
130. Levin EG, DJ Loskutoff: Regulation of plasminogen activator production by cultured endothelial cells. Ann NY Acad Sci 401:184-194, 1982.
131. Gospodarwoicz D, N Ferrara, L Schweigerer: Structural characterization and biological functions of fibroblast growth factor. Endocr Rev 8:95-114, 1987.
132. Unsicker K, H Reichert-Preibsch, R Schmidt: Astroglial and fibroblast growth factors have neurotrophic functions for cultured peripheral and central nervous system neurons. Proc Natl Acad Sci USA 84:5459-5463, 1987.
133. Moscatelli D, M Presta, DB Rifkin: Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis and migration. Proc Natl Acad Sci USA 83:2091-2095, 1986.
134. Presta M, D Moscatelli, J Joseph-Silverstein: Purification from a hepatoma cell line of a basic fibroblast growth factor-like molecule which stimulates capillary endothelial cell plasminogen activator production, DNA synthesis and migration. Mol Cell Biol 6:4060-4066, 1986.
135. Saksela O, D Moscatelli, DB Rifkin: The opposing effects of basic fibroblast growth factor and transforming growth factor B on the regulation of plasminogen activator activity in capillary endothelial cells. J Cell Biol 105:957-963, 1987.
136. Bjorkerud S: Impaired fibrinolysis-induced capacity for post-injury phenotype of cultivated human arterial and human atherosclerotic intimal smooth muscle cells. Circ Res 62:1011-1018, 1988.
137. Ross G, J Glomset, B Kariya: A platelet-derived serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci USA 71:1207-1210, 1974.
138. Bowen-Pope DF, R Ross, RA Seifert: Locally acting growth factors for vascular smooth muscle cells: Endogenous synthesis and release from platelets. Circulation 72:735-740, 1985.
139. Lin HS, S Gordon: Secretion of plasminogen activator by hone marrow-derived mononuclear phagocytes and its enhancement by colony-stimulating factors. J Exp Med 150:231-245, 1979.
140. Saksela O, DB Rifkin: Cell-associated plasminogen activation: Regulation and physiological functions. Annu Rev Cell Biol 4: 93-126, 1988.
141. Keski-Oja J, F Blasi, EB Leof: Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor-beta. J Cell Biol 106:451-459, 1988.
142. Zacharski LR, MZ Wojtukiewicz, V Costantini: Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemostas 18:104-116, 1992.
143. Blasi F: Molecular mechanisms of protease-mediated tumor invasiveness. J Surg Oncol (Suppl) 3:21-23, 1993.
144. Nielsen LS, GM Kellerman, N Behrendt: A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J Biol Chem 263:2358-2363, 1988.
145. Roldan AL, MW Cubellis, MT Masucci: Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 9:467-474, 1990.
146. Schmitt M, F Janicke, N Moniwa: Tumor-associated urokinase-type plasminogen activator: Biological and clinical significance. Biol Chem Hoppe Seyler 373:611-622, 1992.
147. Ploug M, E Ronne, N Behrendt: Cellular receptor for urokinase plasminogen activator: Carboxylterminal processing and membrane anchoring by glycosylphosphatidylinositol. J Biol Chem 266:1926-1933, 1991.
148. Hillmen P, SM Lewis, M Bessler: Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 333:1253-1258, 1995.
149. Vassalli JD, D Baccino, D Belin: A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 100:86-92, 1985.
150. Stoppelli MP, A Corti, A Soffientini: Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activators to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA 82:4939-4943, 1985.
151. Appella E, EA Robinson, SJ Ullrich: The receptor-binding sequence of urokinase. A biological function of the growth factor module of protease. J Biol Chem 262:4437-4440, 1987.
152. Blasi F: Surface receptors for urokinase plasminogen activator. Fibrinolysis 2:73-84, 1988.
153. Picone R, EL Kajtaniak, LS Nielsen: Regulation of urokinase receptors in monocyte-like U937 cells by phorbol ester phorbol myristate acetate. J Cell Biol 108:693-702, 1989.
154. Ellis V, MF Scully, VV Kakkar: Plasminogen activator initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem 264:2185-2188, 1989.
155. Ellis V, K Dano: Plasminogen activation by receptor-bound urokinase. Semin Thromb Hemostas 17:194-200, 1991.
156. Ellis V, H Behrendt, K Dano: Plasminogen activation by receptor-bound urokinase: A kinetic study with both cell-associated and isolated receptor. J Biol Chem 266:12752-12758, 1991.
157. Ny T, M Sawdey, D Lawrence: Cloning and sequence of a cDNA coding for the human B-migrating endothelial-cell-type plasminogen activator. Proc Natl Acad Sci USA 83:6776-6780, 1986.
158. Pannekoek H, H Veerman, H Lambers: Endothelial plasminogen activator inhibitor (PAI): A new member of the Serpin gene family. EMBO J 5:2539-2544, 1986.
159. Ginsburg D, R Zeheb, AY Yang: cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest 78:1673-1680, 1986.
160. Wun TC, KK Kretzmer: cDNA cloning and expression of E coli of a plasminogen activator inhibitor (PAI) related to a PAI produced by Hep G2 hepatoma cell. FEBS Lett 210:11-16, 1987.
161. Kruithof EKO, C Tran-Thang, A Ransijn: Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 64:907-913, 1984.
162. Juhan-Vague I, B Moerman, F DeCock: Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 33: 523-530, 1984.
163. Sprengers FD, HMG Princen, T Kooistra: Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2. J Lab Clin Med 105:751-758, 1985.
164. Konttinen YP: Fibrinolysis. Oy Star Ab. Tampere, Finland, 1968, pp 138-146.
165. Sprengers Ed, JW Akkerman, BG Jansen: Blood platelet plasminogen activator inhibitor: Two different pools of endothelial cell type plasminogen activator inhibitors in human blood. Thromb Haemostas 55:325-329, 1986.
166. Kruithof EKO, C Tran-Thang, F Bachmann: Studies on the release of a plasminogen activator inhibitor by human platelets. Thromb Haemostas 55:201-205, 1986.
167. Levin EG, L Santell: Association of a plasminogen activator inhibitor with the growth substrata and membrane of human endothelial cells. J Cell Biol 105:2543-2549, 1987.
168. Kawano T, K Morimoto, Y Uemura: Urokinase inhibitor in human placenta. Nature 217:253-254, 1968.
169. Wohlwend A, D Belin, JD Vassalli: Plasminogen activator-specific inhibitors produced by human monocytes/macrophages. J Exp Med 165:320-339, 1987.
170. Astedt B, I Lacander, T Ny: The placental type plasminogen activator inhibitor PAI-2. Fibrinolysis 1:203-208, 1987.
171. Genton C, EKO Kruithof, WD Schleuning: Phorbolester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase type plasminogen activator in human U-937 lymphoma cell. J Cell Biol 104:705-712, 1987.
172. Belin D, A Wohlwend, WD Schleuning: Facultative polypeptide translocation allows a single mRNA to encode the secreted and cytosolic forms of plasminogen activator inhibitor 2. EMBO J 8:3287-3294, 1989.
173. Kruithof EKO, JD Vassalli, WD Schleuning: Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937. J Biol Chem 261:11207-11213, 1986.
174. Christensen U, L Holmberg, B Blaha: Kinetics of the reaction between urokinase and an inhibitor of fibrinolysis from placental tissue. Thromb Haemostas 48:24-26, 1982.
175. Lecander I, B Astedt: Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma. Br J Haematol 62: 221-228, 1986.
176. Kruithof EKO, MS Baker, CL Bunn: Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 86:4007-4024, 1995.
177. Heeb MJ, F Espana, M Geiger: Immunological identity of heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor 3. J Biol Chem 262:15813-15816, 1987.
178. Baker JB, DA Low, RL Simmer: Protease nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell 21:37-45, 1980.
179. Eaton DL, JB Baker: Evidence that a variety of cultured cells secrete protease nexin and produce a distinct cytoplasmin serine protease inhibitor. J Cell Physiol 117:175-182, 1983.
180. Koide T, D Foster, S Yoshitake: Amino acid sequence of human histidine-rich glycoprotein derived from the nucleotide sequence of its DNA. Biochemistry 25:2220-2225, 1986.
181. Silverstein RL, LLK Leung, RI Nachman: Thrombospondin: A versatile multifunctional glycoprotein. Arteriosclerosis 6:245-253, 1986.
182. Takahashi K, HC Kwaan, E Koh: Enzymatic properties of the phosphorylated urokinase-type plasminogen activator isolated from a human carcinomatous cell line. Biochem Biophys Res Commun 182:1473-1481, 1992.
183. Takahashi K, HC Kwaan, K Ikeo: Phosphorylation of a surface receptor bound urokinase type plasminogen activator in a human metastatic carcinomatous cell line. Biochem Biophys Res Commun 182:1466-1472, 1992.
184. Melzer MS: Macrophage activation for tumor cytotoxicity characterization of primary and trigger signals during lymphokine activation. J Immunol 127:179-183, 1981.
185. Hanna N: Expression of metastatic potential of tumor cells in young nude mice is correlated with low levels of NK cell-mediated cytotoxicity. Int J Cancer 26:675-680, 1980.
186. Rosenbert SA, P Spiess, R Lafrenier: A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 223:1318-1321, 1986.
187. Rosenstein M, I Yoon, Y Kaufman: Lymphokine activated killer cells: Lysis of fresh syngeneic NK-resistant murine tumor cells by lymphocytes cultured in interleukin-2. Cancer Res 44:1946-1953, 1984.
188. Maasilta P, EM Salonen, A Vaheri: Procollagen-III in serum, plasminogen activation and fibronectin in bronchoalveolar lavage fluid during and following irradiation of human lung. Int J Radiat Oncol Biol Phys 20:973-980, 1991.
189. Harvey SR, JR Loftus, EL Hurley: Characterization of a family of high-molecular-weight plasminogen activators secreted by a lung tumor cell line. Biochim Biophys Acta 1078:360-368, 1991.
190. Orstein DL, LR Zacharski, VA Memoli: Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissues. Cancer 68:1061-1067, 1991.
191. Itoh H, H Kataoka, H Koita: Establishment of a new human cancer cell line secreting protease nexin-II/amyloid beta protein precursor derived from squamous-cell carcinoma of lung. Int J Cancer 49:436-443, 1991.
192. Heidtmann HH, K Havemann, R Schwartz-Albiez: Regulation of the plasminogen activator system in non-small cell lung cancer cell lines by growth factors EGF, TGF-alpha and TGF-beta. Br J Cancer 65:154-156, 1992.
193. Nagayama M, A Sato, H Hayakawa: Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination. Cancer 73:1398-1405, 1994.
194. Albo D, JP Arnoletti, A Castiglioni: Thrombospondin (TSF) and transforming growth factor beta 1 (TGF-beta) promote human A549 lung carcinoma cell plasminogen activator inhibitor type 1 (PAI-1) production and stimulate tumor cell attachment in vitro. Biochem Biophys Res Commun 203:857-865, 1994.
195. Pedersen H, N Brunner, D Francis: Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 54:4671-4675, 1994.
196. Liu G, MA Shuman, RL Cohen: Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer 60:501-506, 1995.
197. Pappot H, N Brunner: The plasminogen activation system and its role in lung cancer. A review. Lung Cancer 12:1-12, 1995.
198. Rodriguez-Panadero F, A Segado, JJ Martin: Failure of talc pleurodesis is associated with increased pleural fibrinolysis. Am J Respir Crit Care Med 151:785-790, 1995.
199. Janicke F, M Schmitt, K Ulm: The urokinase type plasminogen activator (uPA) antigen is related to early relapse in breast cancer. Lancet 2:1049, 1989.
200. Duffy MJ, P O'Grady, D Devaney: Tissue plasminogen activator, a new prognostic marker in breast cancer. Cancer Res 48:1348-1349, 1988.
201. Duffy MJ, P O'Grady, D Devaney: Urokinase plasminogen activator: A marker for aggressive breast carcinomas: Preliminary report. Cancer 52:531-533, 1988.
202. Janicke F, M Schmitt, H Graeff: Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemostas 17:303-313, 1991.
203. Janicke F, M Schmitt, R Hafter. Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4:69-78, 1990.
204. Layer GT, KG Bernard, PJ Gaffney: Tissue plasminogen activators in breast cancer. Thromb Res 45:601-607, 1987.
205. Mira-y-Lopez R, MP Osborne, AJ DePalo: Estradiol modulation of plasminogen activator production in organ cultures of human breast carcinomas; correlation with clinical outcome of anti-estrogen therapy. Int J Cancer 47:827-832, 1991.
206. Duffy MJ, D Reilly, C O'Sullivan: Urokinase plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50:6827-6829, 1990.
207. Duffy MJ, D Reilly, C O'Sullivan: Urokinase plasminogen activator and prognosis in breast cancer. Lancet 1:108, 1990.
208. Reilly D, P Andreasen, MJ Duffy: Urokinase type plasminogen activator and its inhibitor PAI-1 in breast cancer: Studies at both protein and mRNA levels. J Biochem Soc Trans 19:44S, 1991.
209. Schmitt M, L Goretzki, F Janicke: Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer. Biomed Biochim Acta 50:731-741, 1991.
210. Costantini V, LR Zacharski, VA Memoli: Occurrence of components of fibrinolysis pathways in situ in neoplastic and non-neoplastic human breast tissue. Cancer Res 51:354-358, 1991.
211. Reilly D, PA Andreasen, MJ Duffy: Urokinase-plasminogen activator in breast cancer: Assay by both catalytic and immunoassay. Blood Coag Fibrinolysis 2:47-50, 1991.
212. Reilly D, L Christensen, M Duch: Type 1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer 50:208-214, 1992.
213. Christensen L: The distribution of fibronectin, laminin and tetranectin in human breast cancer with special attention to the extracellular matrix. APMIS Suppl 26:1-39, 1992.
214. Yamashita J, K Inada, S Yamashita: Tissue-type plasminogen activator is involved in skeletal metastasis from human breast cancer. Int J Clin Lab Res 21:227-230, 1992.
215. Deng G, G Royle, D Seiffert: The PAI-1/vitronectin interaction. Thromb Haemostas 74:66-70, 1995.
216. Sumiyoshi K, K Serizawa, T Urano: Plasminogen activator system in human breast cancer. Int J Cancer 50:345-348, 1992.
217. Ronnov-Jessen L, B Van Deurs, M Nielsen: Identification, paracrine generation, and possible function of human breast carcinoma myofibroblasts in culture. In Vitro Cell Dev Biol 28A: 273-283, 1992.
218. Spyratos F, PM Martin, K Hacene: Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 84:1266-1272, 1992.
219. Foekens JA, M Schmitt, WL van Putten: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52:6101-6105, 1992.
220. Janicke F, M Schmitt, L Fache: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24:195-208, 1993.
221. Jankowski J, C Ramlau, Z Kopczynski: The influence of tamoxifen on plasma coagulation and serous fibrinolysis. Eur J Gynaecol Oncol 14(Suppl):155-158, 1993.
222. Relia C, M Coviello, M Quaranta: Tissue-type plasminogen activator as marker of functional steroid receptors in human breast cancer. Thromb Res 69:209-220, 1993.
223. Yamashita J, M Ogawa, K Inada: Breast cancer prognosis is poor when total plasminogen activator activity is low. Br J Cancer 67: 374-378, 1993.
224. Anonymous. Effects of chemoendocrine therapy on the coagulation-fibrinolytic systems in patients with advanced breast cancer. Japan Advanced Breast Cancer Study Group and Japan Clinical Oncology Group. Jpn J Cancer Res 84:455-461, 1993.
225. Pyke C, N Graem, E Ralfkiaer: Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 53:1911-1915, 1993.
226. Visscher DW, F Sarker, P LoRusso: Immunohistologic evaluation of invasion-associated proteases in breast carcinoma. Mod Pathol 6:302-306, 1993.
227. Frixen UH, Y Nagamine: Stimulation of urokinase-type plasminogen activator expression by blockage of E-cadherin-dependent cell-cell adhesion. Cancer Res 53:3618-3623, 1993.
228. Yamashita J, M Ogawa, S Yamashita: Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer. Br J Cancer 68:524-529, 1993.
229. Pemberton KD, E Melissari, VV Kakkar: The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis. Blood Coag Fibrinolysis 4:935-942, 1993.
230. Bianchi E, RL Cohen, AT Thor: The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 54:861-866, 1994.
231. Bastholm L, F Elling, N Brunner: Immunoelectron microscopy of the receptor for urokinase plasminogen activator and cathepsin D in the human breast cancer cell line MDA-MB-231. APMIS 102:279-286, 1994.
232. Romer J, C Pyke, LR Lund: Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion. Int J Cancer 57:553-560, 1994.
233. Janicke F, L Pache, M Schmitt: Both the cytosol and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type I. Cancer Res 54: 2527-2530, 1994.
234. Damjanovich L, C Turzo, R Adany: Factors involved in the plasminogen activation system in human breast tumours. Thromb Haemostas 71:684-691, 1994.
235. Foekens JA, M Schmitt, WL van Putten: Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12:1648-1658, 1994.
236. Bouchet C, F Spyratos, PM Martin: Prognostic value of urokinase-type plasminogen activator and 2 inhibitors PAI-1 and PAI-2 in breast cancer. Bull Cancer 81:770-779, 1994.
237. Duffy MJ, D Reilly, E McDermott: Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer 74:2276-2280, 1994.
238. Carriero MV, P Franco, S Del Vecchio: Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies. Cancer Res 54:5445-5454, 1994.
239. Hubbard AL, J Lauder, RA Hawkins: Disregulation of urokinase plasminogen activator gene in breast cancer. Eur J Cancer 31A: 103-107, 1995.
240. Hamada J, H Nagayasu, M Takayama: Enhanced effect of epidermal growth factor on pulmonary metastasis and in vitro invasion of rat mammary carcinoma cells. Cancer Lett 89:161-167, 1995.
241. Ronne E, G Hoyer-Hansen, N Brunner: Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat 33:199-207, 1995.
242. Duggan C, T Maguire, E McDermott: Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 61:597-600, 1995.
243. Yamashita J, M Ogawa, K Sakai: Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer. Surgery 117:601-608, 1995.
244. Evans DM, PL Lin: Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor. Am Surg 61:692-696, 1995.
245. DeBruin PA, G Griffioen, HW Verspaget: Plasminogen activators and tumor development in the human colon: Activity levels in normal mucosa, adenomatous tissues, polyps and adenocarcinomas. Cancer Res 47:L4645-4657, 1987.
246. Markus G, SM Camiolo, S Kohga: Plasminogen activator secretion of human tumors in short-term organ cultures, including a comparison of primary and metastatic colon tumors. Cancer Res 43:5517-5525, 1983.
247. Kohga S, SR Harvery, RM Weaver: Localization of plasminogen activators in human colon cancer by immunoperoxidase staining. Cancer Res 45:1787-1796, 1985.
248. Boyd D, G Florent, P Kim: Determinations of the levels of urokinase and its receptors in human colon carcinoma cell lines. Cancer Res 48:3112-3116, 1988.
249. DeBruin PAF, G Griffioen, HW Verspaget: Plasminogen activator profiles in neoplastic tissues of the human colon. Cancer Res 48:4520-4524, 1988.
250. Boyd D, B Ziober, S Chakrabarty: Examination of urokinase protein/transcript levels and their relationship with laminin degradation in cultured colon carcinoma. Cancer Res 49:816-820, 1989.
251. Schlechte W, G Murano, D Boyd: Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation. Cancer Res 49:6064-6069, 1989.
252. Eriksen J, F Blasi, K Dano: Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 138: 1059-1067, 1991.
253. Hollas W, D Boyd: Urokinase-dependent proteolysis in cultured colon cancer is directed by its receptors. Semin Thromb Hemostas 17:225-230, 1991.
254. Marutsuka K, J Suzumiya, H Kataoka: Correlation between urokinase-type plasminogen activator production and the metastatic ability of human rectal cancer cells. Invasion Metastasis 11:181-191, 1991.
255. Grondahl-Hansen J, E Ralfkiaer, LT Kirkeby: Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol 138:111-117, 1991.
256. Kawanishi H, K Tanaka, S Takai: Immunohistochemical analysis of plasminogen activator expression in human colorectal carcinomas: Correlation with CEA distribution and tumor cell kinetics. J Surg Oncol 46:246-256, 1991.
257. Fukao H, N Tanaka, S Ueshima: Plasminogen activator inhibitor in stomach and colorectal carcinomas. Semin Thromb Hemostas 17:276-279, 1991.
258. Pyke C, P Kristensen, E Ralfkiaer: The plasminogen activation system in human colon cancer: Messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res 51:4067-4071, 1991.
259. Sier CF, HW Verspaget, G Griffioen: Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis. Gastroenterology 101:1522-1528, 1991.
260. Hollas W, E Soravia, A Mazar: Decreased urokinase receptor expression by overexpression of the plasminogen activator in a colon cancer cell line. Biochem J 285:629-634, 1992.
261. Wewer UM, R Albrechtsen: Tetranectin, a plasminogen kringle 4-binding protein. Cloning and gene expression pattern in human colon cancer. Lab Invest 67:253-262, 1992.
262. Sier CF, PH Quax, HJ Vloedgraven: Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases. Invasion Metastasis 13:277-288, 1993.
263. Koretz K, P Moller, R Schwartz-Albiez: Plasminogen activators and plasminogen activator inhibitors in human colorectal carcinoma tissues are not expressed by the tumour cells. Eur J Cancer 29A:1184-1189, 1993.
264. Pyke C, E Ralfkiaer, K Tryggvason: Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol 142:359-365, 1993.
265. Reiter LS, E Kruithof, JF Cajot: The role of the urokinase receptor in extracellular matrix degradation by HT29 human colon carcinoma cells. Int J Cancer 53:444-450, 1993.
266. Buo L, T Lyberg, L Jorgensen: Location of plasminogen activator (PA) and PA inhibitor in human colorectal adenocarcinomas. APMIS 101:235-241, 1993.
267. Huber K, JC Kirchheimer, A Sedlmayer: Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: Comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen. Cancer Res 53:1788-1793, 1993.
268. van Duijnhoven EM, FA Lustermans, JW van Wersch: Evaluation of the coagulation/fibrinolysis balance in patients with colorectal cancer. Haemostasis 23:168-172, 1993.
269. Gluszko P, A Undas, S Amenta: Administration of gamma interferon in human subjects decreases plasminogen activation and fibrinolysis without influencing C1 inhibitor. J Lab Clin Med 123:232-240, 1994.
270. Shah V, S Kumar, KA Zirvi: Metastasis of human colon tumor cells in vivo: Correlation with the overexpression of plasminogen activators and 72 kDa gelatinase. In Vivo 8:321-326, 1994.
271. Webb G, MS Baker, J Nicholl: Chromosomal localization of the human urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 genes: Implications in colorectal cancer. J Gastroenterol Hepatol 9:340-343, 1994.
272. Ganesh S, CF Sier, G Griffioen: Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 54:4065-4071, 1994.
273. Gibson PR, O Rosella, G Rosella: Butyrate is a potent inhibitor of urokinase secretion by normal colonic epithelium in vitro. Gastroenterology 107:410-419, 1994.
274. Mulcahy HE, MJ Duffy, D Gibbons: Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 344:583-584, 1994.
275. Wang H, J Skibber, J Juarez: Transcriptional activation of the urokinase receptor gene in invasive colon cancer. Int J Cancer 58: 650-657, 1994.
276. Wang Y, CJ Jones, J Dang: Human urokinase receptor expression is inhibited by amiloride and induced by tumor necrosis factor and phorbol ester in colon cancer cells. FEBS Lett 353:138-142, 1994.
277. Sier CF, HJ Vloedgraven, S Ganesh: Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology 107:1449-1456, 1994.
278. Tan K, DG Powe, T Gray: Regional variations of urokinase-type plasminogen activator in human colorectal cancer: A quantitative study by image analysis. Int J Cancer 60:308-314, 1995.
279. Naitoh H, Y Eguchi, H Ueyama: Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer. Jpn J Cancer Res 86:48-56, 1995.
280. Dang J, Y Wang, WF Doe: Sodium butyrate inhibits expression of urokinase and its receptor mRNAs at both transcription and post-transcription levels in colon cancer cells. FEBS Lett 359: 147-150, 1995.
281. Sier CF, HJ Vloedgraven, G Griffioen: Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis. Br J Cancer 71:393-396, 1995.
282. Wang Y, J Dang, X Liang: Amiloride modulates urokinase gene expression at both transcription and post-transcription levels in human colon cancer cells. Clin Exp Metastasis 13:196-202, 1995.
283. Sata T, G Nishimura, Y Yonemura: Association of immunohistochemical detection of urokinase-type plasminogen activator with metastasis and prognosis in colorectal cancer. Oncology 52:347-352, 1995.
284. Sappino AP, D Belin, J Huarte: Differential protease expression by cutaneous squamous and basal cell carcinomas. J Clin Invest 88:1073-1079, 1991.
285. Kook YH, J Adamski, A Zelent: The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 13:3983-3991, 1994.
286. Petruzzelli GJ, CH Snyderman, JT Johnson: In vitro urokinase type plasminogen activator levels and total plasminogen activator activity in squamous cell carcinomas of the head and neck. Arch Otolaryngol Head Neck Surg 120:989-992, 1994.
287. Clayman G, SW Wang, GL Nicolson: Regulation of urokinase-type plasminogen activator expression in squamous-cell carcinoma of the oral cavity. Int J Cancer 54:73-80, 1993.
288. Wilson EL, P Jacobs, EB Dowdle: The effects of dexamethasone and tetradecanoylphorbol acetate on plasminogen activator release by human acute myeloid leukemia cells. Blood 61:561-567, 1983.
289. Wilson EL, P Jacobs, EB Dowdle: The secretion of plasminogen activators by human myeloid leukemic cells in vitro. Blood 61: 568-574, 1983.
290. Wilson EL, P Jacobs, L Oliver: Plasminogen activator as a prognostic factor in haematological malignancies. In: Neth R (Ed): Haematology and Blood Transfusion. Springer-Verlag, Berlin, 1985, pp 197-199.
291. Stephens RW, R Alitalo, H Tapiovaara: Production of an active urokinase by leukemia cell lines: A novel distinction from cell lines of solid tumors. Leuk Res 12:419-422, 1988.
292. Alving BM, C Krishnamurti, YP Liu: Stimulated production of urokinase by plasminogen activator inhibitor 2 by the human promyelocytic leukemia cell line HL-60. Thromb Res 51:175-185, 1988.
293. Oliver LO, M Keeton, EL Wilson: Regulation and secretion of plasminogen activators and their inhibitors in a human leukemic cell line (K562). Blood 74:1321-1327, 1989.
294. Tapiovaara H, A Vaheri, R Alitalo: Enhanced activation of pro-urokinase by human RC2A leukemia cells. Semin Thromb Hemostas 17:251-261, 1991.
295. Wilson EL, P Jacobs, GE Francis: Secretion of plasminogen activators by normal bone marrow cells. Leukaemic myeloid cells. Fibrinolysis 6(Suppl 1): 77-79, 1992.
296. Kwaan HC, HN Keer, JA Radosevich: Components of the plasminogen-plasmin system in human tumor cell lines. Semin Thromb Hemostas 17:175-182, 1991.
297. Wilson EL, GE Francis: Differentiation-linked secretion of urokinase and tissue plasminogen activator by normal human haematopoietic cells. J Exp Med 165:1609-1623, 1987.
298. Lyons RM, J Keski-Oja, HL Moses: Proteolytic activation of latent transforming growth factor B from fibroblast conditioned medium. J Cell Biol 106:1659-1665, 1988.
299. Sato Y, R Tsuboi, R Lyons: Characterization of the activation of latent TGFB by co-cultures of endothelial cells and pericytes or smooth muscle cells: A self-regulating system. J Cell Biol 111: 757-763, 1990.
300. Hazuda DJ, J Stricker, P Simon: Structure-function mapping of interleukin 1 precursors. J Biol Chem 266:7081-7086, 1991.
301. Collins AJ, CD Bloomfield, BA Peterson: Acute promyelocyte leukemia. Arch Intern Med 138:1677-1680, 1978.
302. Sakata Y, T Murakami, A Noro: The specific activity of plasminogen activator inhibitor 1 in disseminated intravascular coagulation with acute promyelocytic leukemia. Blood 77:1949-1957, 1991.
303. Tallman MS, HC Kwaan: Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 79:543-553, 1992.
304. Kwaan HC: The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev 11:291-311, 1992.
305. Scherrer A, EK Kruithof, JP Grob: Plasminogen activator inhibitor-2 in patients with monocytic leukemia. Leukemia 5:479-486, 1991.
306. Sherer ME, S Shekhter-Levin, JR Krause: Atypical (7;19) translocation in acute myelomonocytic leukemia. Cancer Genet Cytogenet 57:169-173, 1991.
307. Tapiovaara H, R Alitalo, R Stephens: Abundant urokinase activity on the surface of mononuclear cells from blood and bone marrow of acute leukemia patients. Blood 82:914-919, 1993.
308. Wada H, M Tanigawa, Y Wakita: Increased plasma level of interleukin-6 in disseminated intravascular coagulation. Blood Coag Fibrinolysis 4:583-590, 1993.
309. Tallman MS, D Hakimian, HC Kwaan: New insights into the pathogenesis of coagulation dysfunction in acute promyelocytic leukemia. Leuk Lymphoma 11:27-36, 1993.
310. Cetkovsky P, V Koza, V Cepelak: The significance of plasminogen activator inhibitor 2 in patients with hematologic malignancies. Vnitr Lek 39:871-875, 1993.
311. Plesner T, E Ralfkiaer, M Wiltrup: Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. Am J Clin Pathol 102:835-841, 1994.
312. Kirchheimer J, A Loller, BR Binder: Isolation and characterisation of plasminogen activators from hypersplenic and malignant prostate tissue. Biochim Biophys Acta 797:256-265, 1984.
313. Koller A, J Kirchheimer, H Pflüger: Tissue plasminogen activator activity in prostate cancer. Eur Urol 10:389-394, 1984.
314. Kirchheimer JC, H Pflüger, P Ritschal: Plasminogen activator activity in bone metastasis as compared to primary tumors. Invasion Metastasis 5:344-355, 1985.
315. Hienert G, JC Kirchheimer, H Pflüger: Urokinase type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas. J Urol 140:1466-1469, 1988.
316. Gaylis FD, HN Keer, MJ Wilson: Plasminogen activator in human prostate cancer cell lines and tumors. Correlation with aggressive phenotype. J Urol 142:193-198, 1989.
317. Keer HN, FD Gaylis, JM Kozlowski: Heterogeneity in cellular level of expression of plasminogen activators in human prostate cancer cell lines. Invasive cells contain and secrete more uPA. Prostate 18:201-204, 1991.
318. Hoosein NM, D Boyd, WJ Hollas: Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. Cancer Commun 3:255-264, 1991.
319. Wojtukiewicz MZ, LR Zacharski, VA Memoli: Fibrin formation on vessel walls in hyperplastic and malignant prostate tissue. Cancer 67:1377-1383, 1991.
320. Hasui Y, K Marutsuka, S Nishi: The relationship between cardiovascular complications of estrogen therapy and fibrinolysis in patients with prostatic cancer. Prostate 21:35-39, 1992.
321. Hollas W, N Hoosein, LW Chung: Expression of urokinase and its receptor in invasive and noninvasive prostate cancer cell lines. Thromb Haemostas 68:662-666, 1992.
322. Koutsilieris M, G Frenette, C Lazure: Urokinase-type plasminogen activator: A paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases. Anticancer Res 13:481-486, 1993.
323. Koutsilieris M: Osteoblastic metastasis in advanced prostate cancer. Anticancer Res 13:443-449, 1993.
324. Crowley CW, RL Cohen, BK Lucas: Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 90: 5021-5025, 1993.
325. Lehmann K, E Plas, K Gautschi: Prognostic value of urokinase plasminogen activator for prostatic carcinoma. Urol Int 52:159-161, 1994.
326. Yoshida H, EN Verrusio, H Mihara: Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin. Cancer Res 54:3300-3304, 1994.
327. Billstrom A, I Lecander, F Dagnaes-Hansen: Differential expression of uPA in an aggressive (DU 145) and a nonaggressive (1013L) human prostate cancer xenograft. Prostate 26:94-104, 1995.
328. Billstrom A, B Hartley-Asp, I Lecander: The urokinase inhibitor p-aminobenzamidine inhibits growth of a human prostate tumor in SCID mice. Int J Cancer 61:542-547, 1995.
329. Sugimura M, H Kobayashi, N Kanayama: Clinical significance of urokinase-type plasminogen activator (uPA) in invasive cervical cancer of the uterus. Gynecol Oncol 46:330-336, 1992.
330. Fujishiro S, H Kobayashi, T Terao: Urokinase-type plasminogen activator as a predictor for lymph nodes metastasis of uterine cervical cancer. Nippon Sanka Fujinka Gakkai Zasshi 46:129-136, 1994.
331. Kobayashi H, S Fujishiro, T Terao: Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res 54:6539-6548, 1994.
332. Bulleti C, VM Jasonni, V Polli: Basement membrane in human endometrium: Possible role of proteolytic enzymes in developing hyperplasia and carcinoma. Ann NY Acad Sci 622:376-382, 1991.
333. Tanaka N, S Sekiya, H Takamizawa: Characterization of a 54 kDa, alpha 1-antitrypsin-like protein isolated from ascitic fluid of an endometrial cancer patient. Jpn J Cancer Res 82:693-700, 1991.
334. Gleeson N, R Gonsalves, J Bonnar: The plasminogen activator urokinase and its inhibitor PAI-2 in endometrial cancer. Gynecol Oncol 47:58-61, 1992.
335. Gleeson N, R Gonsalves, J Bonnar: Uterine fibrinolytic enzymes in endometrial cancer. Eur J Gynaecol Oncol 14:369-373, 1993.
336. Gleeson NC, R Gonsalves, J Bonnar: Plasminogen activator inhibitors in endometrial adenocarcinoma. Cancer 72:1670-1672, 1993.
337. Casslen B, B Gustavsson, B Astedt: Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours. Eur J Cancer 27:1445-1448, 1991.
338. Kobayashi H, H Ohi, M Sugimura: Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res 52:3610-3614, 1992.
339. Kobayashi H, H Ohi, H Shinohara: Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion. Br J Cancer 67:537-544, 1993.
340. Kobayashi H, N Moniwa, M Sugimura: Increased cell-surface urokinase in advanced ovarian cancer. Jpn J Cancer Res 84:633-640, 1993.
341. Zacharski LR, VA Memoli, DL Ornstein: Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. J Natl Cancer Inst 85:1225-1230, 1993.
342. Pujade-Lauraine E, H Lu, S Mirshahi: The plasminogen-activation system in ovarian tumors. Int J Cancer 55:27-31, 1993.
343. Hogdall CK, L Christensen, I Clemmensen: The prognostic value of tetranectin immunoreactivity and plasma tetranectin in patients with ovarian cancer. Cancer 72:2415-2422, 1993.
344. Dalet-Fumeron V, N Guinec, M Pagano: In vitro activation of pro-cathepsin B by three serine proteinases: Leukocyte elastase, cathepsin G, and the urokinase-type plasminogen activator. FEBS Lett 332:251-254, 1993.
345. Pedersen N, M Schmitt, E Ronne: A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest 92:2160-2167, 1993.
346. Kobayashi H, H Shinohara, H Ohi: Urinary trypsin inhibitor (UTI) and fragments derived from UTI by limited proteolysis efficiently inhibit tumor cell invasion. Clin Exp Metastasis 12:117-128, 1994.
347. Dumler I, T Petri, WD Schleuning: Induction of c-fos gene expression by urokinase-type plasminogen activator in human ovarian cancer cells. FEBS Lett 343:103-106, 1994.
348. Young TN, GC Rodriguez, TL Moser: Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. Am J Obstet Gynecol 170:1285-1296, 1994.
349. Kuhn W, L Pache, B Schmalfeldt: Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol 55:401-409, 1994.
350. Chambers SK, Y Wang, RE Gertz: Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase. Cancer Res 55:1578-1585, 1995.
351. Miyagi E, H Yasumitsu, F Hirahara: Characterization of matrix-degrading proteinases and their inhibitors secreted by human gynecological carcinoma cells. Jpn J Cancer Res 86:568-576, 1995.
352. Wilhelm O, M Schmitt, S Hohl: Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin Exp Metastasis 13:296-302, 1995.
353. Schneider HG, EH Allan, JM Moseley: Specific down-regulation of parathyroid hormone (PTH) receptors and responses to PTH by tumour necrosis factor alpha and retinoic acid in UMR 106-06 osteoblast-like osteosarcoma cells. Biochem J 280:451-457, 1991.
354. Jankun J: Antitumor activity of the type 1 plasminogen activator inhibitor and cytotoxic conjugate in vitro. Cancer Res 52:5829-5832, 1992.
355. Campbell PG, K Wines, TB Yanosick: Binding and activation of plasminogen on the surface of osteosarcoma cells. J Cell Physiol 159:1-10, 1994.
356. Hakel C, Y Ueda, H Tsuchya: Plasminogen activators and their inhibitor in osteosarcomas and other bone tumors. Zentralbl Pathol 140:363-369, 1994.
357. Sawaya R, OJ Ramo, P Glas-Greenwalt: Plasma fibrinolytic profile in patients with brain tumors. Thromb Haemostas 65:15-19, 1991.
358. Sawaya R, OJ Ramo, ML Shi: Biological significance of tissue plasminogen activator content in brain tumors. J Neurosurg 74:480-486, 1991.
359. Kinder DH, MS Berger, BA Mueller: Urokinase plasminogen activator is elevated in human astrocytic gliomas relative to normal adjacent brain. Oncol Res 5:409-414, 1993.
360. Bindal AK, M Hammoud, WM Shi: Prognostic significance of proteolytic enzymes in human brain tumors. J Neurooncol 22:101-110, 1994.
361. Mohanam S, RE Sawaya, M Yamamoto: Proteolysis and invasiveness of brain tumors: Role of urokinase-type plasminogen activator receptor. J Neurooncol 22:153-160, 1994.
362. Caccamo DV, ME Keohane, PE McKeever: Plasminogen activators and inhibitors in gliomas: An immunohistochemical study. Mod Pathol 7:99-104, 1994.
363. Landau BJ, HC Kwaan, EN Verrusio: Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors. Cancer Res 54:1105-1108, 1994.
364. Sutton R, ME Keohane, SR VanderBerg: Plasminogen activator inhibitor-1 in the cerebrospinal fluid as an index of neurological disease. Blood Coag Fibrinolysis 5:167-171, 1994.
365. Yamamoto M, R Sawaya, S Mohanam: Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. Cancer Res 54:3656-3661, 1994.
366. Yamamoto M, R Sawaya, S Mohanam: Expression and cellular localization of messenger RNA for plasminogen activator inhibitor type 1 in human astrocytomas in vivo. Cancer Res 54:3329-3332, 1994.
367. Hsu DW, JT Efird, ET Hedley-Whyte: Prognostic role of urokinase-type plasminogen activator in human gliomas. Am J Pathol 147:114-123, 1995.
368. Umehara Y, T Kimura, M Yoshida: Relationship between plasminogen activators and stomach carcinoma stage. Acta Oncol 30:815-818, 1991.
369. Takai S, M Yamamura, K Tanaka: Plasminogen activators in human gastric cancers: Correlation with DNA ploidy and immunohistochemical staining. Int J Cancer 48:20-27, 1991.
370. Nakamura M, H Konno, T Tanaka: Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissues. Thromb Res 65:709-719, 1992.
371. Koshikawa N, H Yasumitsu, M Umeda: Multiple secretion of matrix serine proteinases by human gastric carcinoma cell lines. Cancer Res 52:5046-5053, 1992.
372. Wang N, E Planus, M Pouchelet: Urokinase receptor mediates mechanical force transfer across the cell surface. Am J Physiol 268 (Cell Physiol 51):C1062-C1066, 1995.
373. Nekarda H, M Schmitt, K Ulm: Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 54:2900-2907, 1994.
374. Heiss MM, R Babic, H Allgayer: Tumor-associated proteolysis and prognosis: New functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol 13:2084-2093, 1995.
375. Huber K, JC Kirchheimer, D Ermler: Determination of plasma urokinase-type plasminogen activator antigen in patients with primary liver cancer: Characterization as tumor-associated antigen and comparison with alpha-fetoprotein. Cancer Res 52:1717-1720, 1992.
376. Fitch P, B Bennett, NA Booth: Distribution of plasminogen activator inhibitor in normal liver, cirrhotic liver, and liver with metastases. J Clin Pathol 47:218-221, 1994.
377. Boothman DA, M Wang, SW Lee: Induction of tissue-type plasminogen activator by ionizing radiation in human malignant melanoma cells. Cancer Res 51:5587-5595, 1991.
378. Supino R, E Mapelli, O Sanfilippo: Biological and enzymatic features of human melanoma clones with different invasive potential. Melanoma Res 2:377-384, 1992.
379. Mimura K, K Sueishi, C Yasunaga: Fibrinolysis activity promotes tumor invasiveness of B16 melanoma cell lines through a reconstituted gel matrix. Invasion Metastasis 12:24-34, 1992.
380. Montgomery AM, YA De Clerck, KE Langley: Melanoma-mediated dissolution of extracellular matrix: Contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways. Cancer Res 53:693-700, 1993.
381. Denijn M, DJ Ruiter: The possible role of angiogenesis in the metastatic potential of human melanoma. Clinicopathological aspects. Melanoma Res 3:5-14, 1993.
382. Weidle UH, E Wollisch, E Ronne: Studies on functional and structural role of urokinase receptor and other components of the plasminogen activation system in malignancy. Ann Biol Clin 52:775-782, 1994.
383. deVries TJ, PH Quax, M Denijn: Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 144:70-81, 1994.
384. Stahl A, BM Mueller: Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 54:3066-3071, 1994.
385. Delbaldo C, I Masouye, JH Saurat: Plasminogen activation in melanocytic neoplasia. Cancer Res 54:4547-4552, 1994.
386. Nip J, SA Rabbani, HR Shibata: Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells. J Clin Invest 95:2096-2103, 1995.
387. Andren-Sandberg A, I Lecander, G Martinsson: Peaks in plasma plasminogen activator inhibitor-1 concentration may explain thrombotic events in cases of pancreatic carcinoma. Cancer 69:2884-2887, 1992.
388. Kuramoto M, J Yamashita, M Ogawa: Tissue-type plasminogen activator predicts endocrine responsiveness of human pancreatic carcinoma cells. Cancer 75:1263-1272, 1995.
389. Poustis-Delpont C, R Descomps, P Auberger: Characterization and purification of a guanidinobenzoatase: A possible marker of human renal carcinoma. Cancer Res 52:3622-3628, 1992.
390. Bashar H, T Urano, K Fukuta: Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer. Urol Int 52:4-8, 1994.
391. Xu Y, WA See: Regulation of plasminogen activator activity in transitional carcinoma cell lines by wound site growth factors. Surg Oncol 3:175-185, 1994.
392. Marutsuka K, Y Hasui, Y Asada: Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6. Clin Exp Metastasis 13:116-122, 1995.
393. Bizzacchi JM, CAM Sampaio: Plasma prekallikrein, coagulation, and fibrinolytic parameters in myeloma patients. Nouv Rev Fr Hématol 34:201-203, 1992.
394. Cavallaro U, A del Vecchio, DA Lappi: A conjugate between human urokinase and saporin, a type-1 ribosome-inactivating protein, is selectively cytotoxic to urokinase receptor-expressing cells. J Biol Chem 268:23186-23190, 1993.
395. Scott-Coumbes DM, SA Whawell, MN Vipond: Fibrinolytic activity of ascites caused by alcoholic cirrhosis and peritoneal malignancy. Gut 34:1120-1122, 1993.
396. Wojtukiewicz MZ, DG Tang, E Ben-Josef: Solid tumor cells express functional "tethered ligand" thrombin receptor. Cancer Res 55:698-704, 1995.
397. Lomas DA, DL Evans, C Upton: Inhibition of plasmin, urokinase, tissue plasminogen activator, and CIS by a myxoma virus serine proteinase inhibitor. J Biol Chem 268:516-521, 1993.
398. Nykjaer A, B Moller, RF Todd III: Urokinase receptor. An activation antigen in human T lymphocytes. J Immunol 152:505-516, 1994.
399. Wei Y, DA Waltz, N Rao: Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269:32380-32388, 1994.
400. van Aswegen CH, PJ du Toit, DJ du Plessis: Modulation of lipoxidase activity by urokinase-type plasminogen activator. Prostaglandins Leukotrienes Essent Fatty Acids 51:183-186, 1994.
401. Quattrone A, G Fibbi, E Anichini: Reversion of the invasive phenotype of transformed human fibroblasts by anti-messenger oligonucleotide inhibition of urokinase receptor gene expression. Cancer Res 55:90-95, 1995.
402. Shetty S, A Kumar, A Johnson: Urokinase receptor in human malignant mesothelioma cells: Role in tumor cell mitogenesis and proteolysis. Am J Physiol 268:L972-L982, 1995.